Corona Remedies has made the audio recording of its Q1 FY27 earnings conference call available to investors and analysts, providing direct access to management’s commentary on the company’s performance for the quarter ended June 30, 2026. The availability of this recording ensures transparency regarding the unaudited financial results for the first quarter of FY27, allowing stakeholders to review the detailed discussion held with market participants.

The company notified the Listing Operation Department at BSE Limited and the Listing Compliance Department at National Stock Exchange of India Limited on August 03, 2026. This disclosure was made in continuation of a letter dated July 22, 2026, and is compliant with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The regulation mandates timely dissemination of material information to prevent information asymmetry among investors.

The audio recording covers the post-earnings quarterly call where analysts and investors queried the management about the financial outcomes. The session focused on the unaudited financial results for the first quarter and three months ended June 30, 2026. Investors can access the recording directly through the company’s website at the designated URL provided in the exchange filing.

Key Details

Chetna Dharajiya, Company Secretary and Compliance Officer of Corona Remedies Limited, signed the communication. The digital signature was applied on August 03, 2026, at 16:02:47 IST. The filing serves as an official record of the company’s compliance with disclosure norms regarding investor interactions following the release of quarterly financial results.

Corona Remedies reported a 30.1% year-on-year increase in net profit after tax (PAT) to ₹60.1 crore for the first quarter of FY27, driven by a 21.9% surge in revenue from operations to ₹422.4 crore. The pharmaceutical company's improved operational efficiency and focused brand-building initiatives expanded its EBITDA margin by 155 basis points to 22.04%, signaling strong cost management amidst top-line growth.

The Board of Directors approved the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, at a meeting held on July 31, 2026. The results were reviewed by the Audit Committee on July 30, 2026, and subjected to a limited review by Walker Chandiok & Co LLP, the statutory auditors, who issued an unmodified review conclusion. The disclosure was made in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Financial Performance Highlights

Corona Remedies demonstrated robust growth across key financial metrics in Q1FY27 compared to the corresponding period of the previous fiscal year. Revenue from operations increased from ₹346.5 crore to ₹422.4 crore, while net profit after tax rose from ₹46.4 crore to ₹60.1 crore. The following table details the key financial parameters:

Market Position and Operational Milestones

Beyond financial metrics, Corona Remedies strengthened its market standing in the India Prescription Market (IPM). According to Pharmatrac data for June 2026, the company was ranked 26th among the top 30 IPM companies, moving up three places from its 29th rank in June 2025. It remains the fastest-growing company among the top 30 for six consecutive months, outperforming the market by 1.9 times. In the Gynaecology segment, Corona secured the 5th rank, reflecting its therapy leadership.

Operationally, the company inaugurated its EU-GMP approved Female Hormone Manufacturing Facility in Ahmedabad on June 30, 2026, initiating commercialization immediately. Additionally, management highlighted the smooth integration of the acquired brand Wokadine from both supply and distribution perspectives.

What the Numbers Show

The divergence between revenue growth and EBITDA growth underscores significant operating leverage. The expansion in both EBITDA and PAT margins indicates that fixed costs are being effectively spread over a larger revenue base while variable costs remain controlled. This structural improvement, combined with the inauguration of the new hormone manufacturing facility, positions the company for sustained profitability in core therapies such as Women's Healthcare and Cardio-diabetes.

Regulatory Disclosures

The financial results were prepared in accordance with Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013. No exceptional items were reported for the quarter. The full format of the unaudited financial results is available on the company's website and the stock exchanges' websites.